TNF-alpha inhibitor exposure was associated with adjusted hazard ratios of 1.99 for basal cell carcinoma, 1.69 for squamous cell carcinoma, and 1.54 for melanoma in a 56,209-patient retrospective cohort.

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.

ACP updated guidance recommends shared decision-making rather than routine biennial mammography for average-risk women aged 40 to 49, diverging from the USPSTF recommendation.

A physician-owned oncology group in Georgia attributed retention of women oncologists to flexible scheduling, ambient AI documentation, and ownership-model voice in operational decisions.